These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
247 related articles for article (PubMed ID: 24105670)
41. Resistance to targeted cancer drugs through hepatocyte growth factor signaling. Heynen GJ; Fonfara A; Bernards R Cell Cycle; 2014; 13(24):3808-17. PubMed ID: 25426675 [TBL] [Abstract][Full Text] [Related]
42. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Christensen JG; Burrows J; Salgia R Cancer Lett; 2005 Jul; 225(1):1-26. PubMed ID: 15922853 [TBL] [Abstract][Full Text] [Related]
43. Targeted therapy of hepatocellular carcinoma: present and future. Chan SL; Yeo W J Gastroenterol Hepatol; 2012 May; 27(5):862-72. PubMed ID: 22369685 [TBL] [Abstract][Full Text] [Related]
44. Identification of a pivotal endocytosis motif in c-Met and selective modulation of HGF-dependent aggressiveness of cancer using the 16-mer endocytic peptide. Cho KW; Park JH; Park CW; Lee D; Lee E; Kim DJ; Kim KJ; Yoon SH; Park Y; Kim E; Cho S; Jang S; Park BC; Chi SW; Yoo SH; Jang MH; Kim HN; Kim E; Jo K; Park YW Oncogene; 2013 Feb; 32(8):1018-29. PubMed ID: 22525273 [TBL] [Abstract][Full Text] [Related]
45. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Maulik G; Kijima T; Ma PC; Ghosh SK; Lin J; Shapiro GI; Schaefer E; Tibaldi E; Johnson BE; Salgia R Clin Cancer Res; 2002 Feb; 8(2):620-7. PubMed ID: 11839685 [TBL] [Abstract][Full Text] [Related]
46. A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells. Hov H; Holt RU; Rø TB; Fagerli UM; Hjorth-Hansen H; Baykov V; Christensen JG; Waage A; Sundan A; Børset M Clin Cancer Res; 2004 Oct; 10(19):6686-94. PubMed ID: 15475459 [TBL] [Abstract][Full Text] [Related]
47. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. De Bacco F; Luraghi P; Medico E; Reato G; Girolami F; Perera T; Gabriele P; Comoglio PM; Boccaccio C J Natl Cancer Inst; 2011 Apr; 103(8):645-61. PubMed ID: 21464397 [TBL] [Abstract][Full Text] [Related]
48. Preclinical evaluation of biomarkers for response monitoring to the MET inhibitor BAY-853474. Klotz M; Schmid E; Steiner-Hahn K; Rose T; Laube J; Roese L; Henderson D; Krahn T; von Ahsen O Biomarkers; 2012 Jun; 17(4):325-35. PubMed ID: 22452362 [TBL] [Abstract][Full Text] [Related]
49. cMET as a potential therapeutic target in gastric cancer (Review). Teng L; Lu J Int J Mol Med; 2013 Dec; 32(6):1247-54. PubMed ID: 24141315 [TBL] [Abstract][Full Text] [Related]
50. Inhibition of HGF/MET as therapy for malignancy. Naran S; Zhang X; Hughes SJ Expert Opin Ther Targets; 2009 May; 13(5):569-81. PubMed ID: 19397476 [TBL] [Abstract][Full Text] [Related]
51. Green tea (-)-epigallocatechin-3-gallate inhibits HGF-induced progression in oral cavity cancer through suppression of HGF/c-Met. Koh YW; Choi EC; Kang SU; Hwang HS; Lee MH; Pyun J; Park R; Lee Y; Kim CH J Nutr Biochem; 2011 Nov; 22(11):1074-83. PubMed ID: 21292466 [TBL] [Abstract][Full Text] [Related]
52. Transcriptional activation of the hepatocyte growth factor receptor (c-met) gene by its ligand (hepatocyte growth factor) is mediated through AP-1. Seol DW; Chen Q; Zarnegar R Oncogene; 2000 Feb; 19(9):1132-7. PubMed ID: 10713700 [TBL] [Abstract][Full Text] [Related]
53. Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4. Matsumoto K; Nakamura T; Sakai K; Nakamura T Proteomics; 2008 Aug; 8(16):3360-70. PubMed ID: 18646008 [TBL] [Abstract][Full Text] [Related]
54. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Zhang YW; Staal B; Essenburg C; Su Y; Kang L; West R; Kaufman D; Dekoning T; Eagleson B; Buchanan SG; Vande Woude GF Cancer Res; 2010 Sep; 70(17):6880-90. PubMed ID: 20643778 [TBL] [Abstract][Full Text] [Related]
55. A novel recombinant soluble splice variant of Met is a potent antagonist of the hepatocyte growth factor/scatter factor-Met pathway. Tiran Z; Oren A; Hermesh C; Rotman G; Levine Z; Amitai H; Handelsman T; Beiman M; Chen A; Landesman-Milo D; Dassa L; Peres Y; Koifman C; Glezer S; Vidal-Finkelstein R; Bahat K; Pergam T; Israel C; Horev J; Tsarfaty I; Ayalon-Soffer M Clin Cancer Res; 2008 Jul; 14(14):4612-21. PubMed ID: 18628476 [TBL] [Abstract][Full Text] [Related]
56. Targeting the c-MET signaling pathway for cancer therapy. Liu X; Yao W; Newton RC; Scherle PA Expert Opin Investig Drugs; 2008 Jul; 17(7):997-1011. PubMed ID: 18549337 [TBL] [Abstract][Full Text] [Related]
57. The clinical and functional significance of c-Met in breast cancer: a review. Ho-Yen CM; Jones JL; Kermorgant S Breast Cancer Res; 2015 Apr; 17(1):52. PubMed ID: 25887320 [TBL] [Abstract][Full Text] [Related]
58. HGF/c-MET: A Promising Therapeutic Target in the Digestive System Cancers. Zhang H; Feng Q; Chen WD; Wang YD Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30360560 [TBL] [Abstract][Full Text] [Related]
59. Targeting the HGF/c-Met axis: state of play. Yap TA; de Bono JS Mol Cancer Ther; 2010 May; 9(5):1077-9. PubMed ID: 20442310 [No Abstract] [Full Text] [Related]
60. Biological, diagnostic and therapeutic relevance of the MET receptor signaling in head and neck cancer. Nisa L; Aebersold DM; Giger R; Zimmer Y; Medová M Pharmacol Ther; 2014 Sep; 143(3):337-49. PubMed ID: 24786972 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]